System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review English Abstract Ppublish

PubMed: 42439144

[Cytomegalovirus and pregnancy: Challenges and perspectives].

Rev Prat 76(6):622-629

Authors: Charles Egloff, Christelle Vauloup-Fellous, Olivier Picone

Affiliations

  • Service de gynécologie-obstétrique, hôpital Louis-Mourier, AP-HP, Colombes, France.
  • Université Paris Cité, Paris, France.
  • Groupe de recherche sur les infections pendant la grossesse (GRIG), Vélizy-Villacoublay, France.
  • Laboratoire de virologie, centre national de référence pour la rubéole (OMS), hôpitaux universitaires Paris-Saclay, AP-HP, Villejuif, France.
  • Faculté de médecine Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Université Paris-Saclay, Inserm U1184, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France.
  • IAME, Inserm U 1137, Paris, France.
  • FHU PREMA, Paris, France.

Abstract

Cytomegalovirus (CMV), a member of the Herpesviridae family, is the leading infectious cause of congenital neurosensory impairment. This article reviews the key clinical aspects essential for its management during pregnancy and discusses upcoming challenges and future perspectives. In recent years, valacyclovir has demonstrated its efficacy in reducing the risk of maternal-fetal transmission following seroconversion during pregnancy. Based on this evidence, the health-economic evaluation of systematic CMV screening during the first trimester of pregnancy strongly supports its widespread implementation, despite its inability to address secondary infections. Since June 2025, the French National Authority for Health (HAS) has recommended routine screening for CMV infection during the first trimester of pregnancy (for pregnant women whose serostatus is negative or unknown). Emerging antivirals, such as valganciclovir and letermovir, currently under evaluation, could expand treatment options. Finally, research on a vaccine are ongoing, it holds the potential to revolutionize the long-term management of this infection.

MeSH

Pregnancy, Pregnancy Trimester, First, Cytomegalovirus, Infections